A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.

After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.